Literature DB >> 6219841

In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin.

S Poppema, E B Bröcker, L de Leij, D Terbrack, T Visscher, A Ter Haar, E Macher, T H Thé, C Sorg.   

Abstract

Monoclonal antibodies, directed against functionally different lymphocyte subsets, were applied on frozen sections of primary malignant melanomas and benign nevi. Positive reaction was identified by means of an immunoperoxidase method. It was found that lymphocytic infiltrate underneath and in between malignant melanoma is composed of approximately equal numbers of OKT4 positive helper and OKT8 positive suppressor/cytotoxic T cells. The majority of these lymphocytes also expressed HLA-Dr antigen, indicating an activated state. In addition HLA-Dr, OKT6 positive dendritic cells were present in the infiltrate and between the melanoma cells. Finally, melanoma cells expressed demonstrable amounts of HLA A, B, C antigens, whereas benign nevi did not. It is concluded that all ingredients for a successful immune reaction against primary malignant melanoma are on hand. This finding is in agreement with the relatively frequent occurrence of partial or even complete regression of primary malignant melanoma of the skin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6219841      PMCID: PMC1536757     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  A monoclonal antibody with selective reactivity with functionally mature human thymocytes and all peripheral human T cells.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

2.  Spontaneous regression of primary malignant melanomas with regional metastases.

Authors:  J L Smith; J S Stehlin
Journal:  Cancer       Date:  1965-11       Impact factor: 6.860

3.  Spontaneous regression of melanoma.

Authors:  V J McGovern
Journal:  Pathology       Date:  1975-04       Impact factor: 5.306

4.  Evidence by reactivity with hybridoma antibodies for a probable myeloid origin of peripheral blood cells active in natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

Authors:  H D Kay; D A Horwitz
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

5.  A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by a heteroantiserum termed TH2.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

6.  A monoclonal antibody reactive with human peripheral blood monocytes.

Authors:  J Breard; E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  J Immunol       Date:  1980-04       Impact factor: 5.422

7.  HLA restriction of cell-mediated lysis of influenza virus-infected human cells.

Authors:  A J McMichael; A Ting; H J Zweerink; B A Askonas
Journal:  Nature       Date:  1977-12-08       Impact factor: 49.962

8.  Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression.

Authors:  E L Reinherz; P C Kung; J M Pesando; J Ritz; G Goldstein; S F Schlossman
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

9.  Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage.

Authors:  E L Reinherz; P C Kung; G Goldstein; R H Levey; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

10.  Melanoma. An ultrastructural study of the host inflammatory and vascular responses.

Authors:  A M Dvorak; M C Mihm; J E Osage; H F Dvorak
Journal:  J Invest Dermatol       Date:  1980-11       Impact factor: 8.551

View more
  19 in total

Review 1.  Photoimmunology of experimental melanoma.

Authors:  C K Donawho; M L Kripke
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

2.  Tumor-infiltrating lymphocytes from nonrenal urological malignancies.

Authors:  G P Haas; D Solomon; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  CD8+ T lymphocytes are recruited to neoplastic cervix.

Authors:  M C Bell; R P Edwards; E E Partridge; K Kuykendall; W Conner; H Gore; E Turbat-Herrara; P A Crowley-Nowick
Journal:  J Clin Immunol       Date:  1995-05       Impact factor: 8.317

4.  Lymphocyte subpopulations in peripheral blood and bone marrow in patients with idiopathic myelofibrosis.

Authors:  E Vellenga; S Poppema; C G Kallenberg; M R Halie
Journal:  Blut       Date:  1987-08

5.  Identification of lymphocyte subsets and natural killer cells in head and neck cancers. An immunohistological study using monoclonal antibodies.

Authors:  Y Harabuchi; N Yamanaka; A Kataura
Journal:  Arch Otorhinolaryngol       Date:  1985

Review 6.  Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis.

Authors:  J W Kreider; G L Bartlett; B L Butkiewicz
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

7.  The pattern of the mononuclear infiltrate as a prognostic parameter in flat superficial spreading melanomas.

Authors:  E B Bröcker; G Kolde; D Steinhausen; A Peters; E Macher
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

8.  Direct evidence to support the immunosurveillance concept in a human regressive melanoma.

Authors:  A Mackensen; G Carcelain; S Viel; M C Raynal; H Michalaki; F Triebel; J Bosq; T Hercend
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

9.  Macrophages in melanocytic naevi.

Authors:  E B Bröcker; C Reckenfeld; H Hamm; D J Ruiter; C Sorg
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

10.  Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.

Authors:  L Ferradini; A Mackensen; C Genevée; J Bosq; P Duvillard; M F Avril; T Hercend
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.